Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- XERS
- Price
- 4.51
- Stock movement up
- +0.02 (0.26%)
- Company name
- Xeris Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.23B
- Ent value
- 1.52B
- Price/Sales
- 6.54
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- 48.97
- PEG
- -
- EPS growth
- -38.13%
- 1 year return
- 179.04%
- 3 year return
- 59.51%
- 5 year return
- 12.62%
- 10 year return
- -
Last updated: 2025-09-15
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
XERS does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 6.54 |
| Price to Book | - |
| EV to Sales | 8.09 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 161.48M |
| EPS (TTM) | -0.42 |
| FCF per share (TTM) | -0.22 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 187.36M |
| Gross profit (TTM) | 144.31M |
| Operating income (TTM) | -45.17M |
| Net income (TTM) | -63.11M |
| EPS (TTM) | -0.42 |
| EPS (1y forward) | 0.15 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 77.02% |
| Operating margin (TTM) | -24.11% |
| Profit margin (TTM) | -33.69% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 59.23M |
| Net receivables | 41.14M |
| Total current assets | 162.80M |
| Goodwill | 22.86M |
| Intangible assets | 101.63M |
| Property, plant and equipment | 35.32M |
| Total assets | 321.10M |
| Accounts payable | 7.45M |
| Short/Current long term debt | 270.96M |
| Total current liabilities | 91.01M |
| Total liabilities | 349.43M |
| Shareholder's equity | -28.32M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -32.67M |
| Capital expenditures (TTM) | 780.00K |
| Free cash flow (TTM) | -33.45M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -19.66% |
| Return on Invested Capital | -30.20% |
| Cash Return on Invested Capital | -16.00% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 7.60 |
| Daily high | 7.73 |
| Daily low | 7.51 |
| Daily Volume | 1.55M |
| All-time high | 27.23 |
| 1y analyst estimate | 9.00 |
| Beta | 0.86 |
| EPS (TTM) | -0.42 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 6 Nov 2025 |
Downside potential
Loading...
Downside potential data
| XERS | S&P500 | |
| Current price drop from All-time high | -72.13% | -1.46% |
| Highest price drop | -96.22% | -56.47% |
| Date of highest drop | 5 Jan 2023 | 9 Mar 2009 |
| Avg drop from high | -79.54% | -10.99% |
| Avg time to new high | 150 days | 12 days |
| Max time to new high | 1747 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
1.23B
Marketcap category
Small-cap
Description
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Employees
394
Website
Investor relations
-
SEC filings
CEO
Paul R. Edick
Country
USA
City
Chicago
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page